Cibus, Inc. — 2022 Q3 Form 10-Q summary
Entity note: The supplied filing is for Calyxt, Inc. (ticker CLXT), not Cibus, Inc. This summary reflects the filing’s stated issuer and its quarter ended September 30, 2022.
Business context and reporting period
Calyxt described itself as an early-stage plant-based synthetic biology company, focused on its PlantSpring technology platform and BioFactory production system, alongside technology licensing and agricultural-trait development. The filing covers the three and nine months ended September 30, 2022; financial statements are unaudited.
Financial and operating metrics
- Revenue: Q3 revenue was $42,000, versus $7.762 million in Q3 2021. Nine-month revenue was $115,000, versus $24.044 million. 2022 revenue was primarily from development work on a palm-oil alternative.
- Profit and margins: Q3 net loss was $5.950 million, or $0.13 per share, versus a $7.307 million loss, or $0.20 per share. Nine-month net loss was $14.054 million, or $0.31 per share, versus $22.142 million, or $0.60 per share. Gross profit was $42,000 in Q3 and $115,000 for nine months; the reported 100% gross margin reflects nominal revenue and no cost of goods sold, rather than a scaled business.
- Operating costs: Q3 R&D was $3.016 million and SG&A was $3.229 million. Nine-month R&D was $9.207 million and SG&A was $9.965 million. Nine-month adjusted EBITDA loss, a non-GAAP measure, was $14.379 million.
- Cash flow: Operating cash use was $15.601 million for the first nine months, compared with $14.654 million in 2021. Investing activities used $1.509 million; financing activities provided $9.894 million, principally from the February 2022 offering.
- Liquidity: At September 30, cash and cash equivalents were $7.031 million; restricted cash was $174,000, for total cash, cash equivalents, and restricted cash of $7.205 million. Current assets were $7.944 million and current liabilities $4.228 million.
- Debt and obligations: The balance sheet included $13.550 million of non-current operating lease obligations and $120,000 of current financing lease obligations. The filing reports no non-current financing lease obligation at quarter-end. Future operating and financing lease payments totaled $24.824 million before imputed interest.
Changes versus the comparable period
- Revenue and cost of goods sold fell sharply following completion of the soybean product-line wind-down in late 2021 and the shift toward synthetic biology, which had not yet generated significant revenue.
- Operating loss improved to $19.057 million for nine months from $22.622 million. Lower SG&A and the product-line transition contributed, while R&D increased.
- Nine-month net loss improved by $8.088 million, but the comparison includes a $5.083 million non-operating gain, primarily from remeasuring common stock warrants as their fair value declined with the stock price. This was a non-cash item.
- Cash declined from $14.421 million, including restricted cash, at December 31, 2021, to $7.205 million at September 30, 2022. A February offering raised $10.0 million net; the company also issued warrants and its share count increased.
Outlook, risks and unusual items
- Going concern: Management concluded substantial doubt existed about the company’s ability to continue as a going concern, citing the need for additional capital to support its business plan for 12 months or more from the filing date. It estimated existing liquidity, anticipated ATM proceeds, the settlement, and cost reductions could fund operations into the second quarter of 2023. This is not assurance of financing or continued operations.
- Financing and strategy: The board was evaluating alternatives including financing, a merger or other business combination, asset sale, licensing, or other transactions. The ATM was subject to “baby shelf” limits; the filing reports approximately 2.0 million shares sold after October 3 for about $0.1 million net. Further financing or a transaction could substantially dilute shareholders, and no outcome was assured.
- Business outlook: Calyxt reported 132 customer chemistries evaluated, with 43 meeting its target product-profile criteria, and said it was negotiating development agreements. It expected agreements for two or three compounds by year-end, subject to limited capital. A pilot project for a potential large consumer-goods customer was expected to deliver an engineered solution in early 2023. The company also announced successful production of squalene and signed a scale-up agreement with Evologic Technologies.
- Settlement: A November 2022 settlement with a technology vendor provided for two payments of $750,000, one upon execution of an amended services agreement and another by January 31, 2023; the first payment was conditional on execution.
- Other risks: Cost cuts, including headcount reductions and lower capital spending, could impair execution. Cellectis’s lease-guarantee indemnification obligation was triggered after its ownership fell to 50% or less; Cellectis retained significant governance rights. The company transferred its listing to Nasdaq Capital Market in October and remained subject to continued-listing requirements.
Important facts for investors to verify
- Confirm the issuer identity: this filing is Calyxt, Inc., not Cibus, Inc.
- Track cash burn, actual runway, ATM capacity and proceeds, and the timing and receipt of the vendor settlement payments.
- Monitor the board’s strategic-alternatives process, financing availability, and any resulting dilution or changes to operations.
- Verify whether proposed customer development agreements, pilot work, and product commercialization produce contracted revenue and cash receipts.
- Assess warrant-related fair-value volatility, lease commitments, Cellectis’s continuing rights, and Nasdaq listing compliance.